The purpose of this article is to evaluate and compare the safety and efficacy of endovascular management of the portal vein (PV) via percutaneous transsplenic access versus percutaneous transhepatic access in liver transplantation (LT) recipients. A total of 18 patients who underwent endovascular management of PV via percutaneous transhepatic (n 5 8) and transsplenic (n 5 10) access were enrolled. Transsplenic access was chosen if the spleen was located in a normal position, the splenic vein (SpV) was preserved, and the target lesion did not involve confluence of the superior mesenteric and SpVs. Accessibility of the percutaneous transsplenic puncture was confirmed via ultrasound (US) in the angiography suite. All procedures were performed under local anesthesia. Percutaneous transhepatic or transsplenic access was performed using a 21-gauge Chiba needle under US and fluoroscopic guidance, followed by balloon angioplasty, stent placement, or variceal embolization. The access tract was embolized using coils and a mixture (1:2) of glue and ethiodized oil. Transhepatic or transsplenic access was successfully achieved in all patients. A total of 12 patients underwent stent placement; 3 had balloon angioplasty only; 2 had variceal embolization only; and 1 had variceal embolization followed by successful stent placement. Regarding major complications, 1 patient experienced a SpV tear with extravasation during transsplenic balloon angioplasty, which was successfully managed using temporary balloon inflation, followed by transfusion. Clinical success was achieved in 9 of 11 (82%) patients who exhibited clinical manifestations. The remaining 7 patients who underwent prophylactic endovascular management were healthy. In conclusion, endovascular management of PV via percutaneous transsplenic access is a relatively safe and effective alternative that does not damage the liver grafts of LT recipients.
various types of endovascular management of the portal vein (PV). However, this type of access may cause injury to the engrafted liver. In addition, the risk of failure with this type of access may increase if the recipient's intrahepatic PV branches have collapsed due to PV stenosis or occlusion.
Percutaneous transsplenic access is another option for PV access without the risk of liver injury. This type of access can also be applied to a patient with a collapsed intrahepatic PV. A few reports have demonstrated the safety of this access, although it has rarely been used in LT recipients. (1) (2) (3) (4) (5) (6) (7) Our institution has used percutaneous transsplenic access as an alternative to transhepatic access in LT recipients since 2014 with the intent to minimize liver injury during endovascular management of PV. In this article, we compare the safety and efficacy of endovascular management of PV in LT recipients through percutaneous transsplenic access versus percutaneous transhepatic access.
Patients and Methods

PATIENTS
Written informed consent was obtained from each patient or their legal guardian, and the study was approved by our institutional review board (No. 2016-0897) .
From May 2014 through May 2016, 25 LT recipients underwent endovascular management, including balloon angioplasty (n 5 3), stent placement (n 5 13), and/or variceal embolization (n 5 10), to improve PV inflow. A total of 18 patients who underwent percutaneous transhepatic (n 5 8) or transsplenic (n 5 10) access were enrolled in this study. Seven patients who only underwent retrograde transvenous embolization of the splenorenal shunt via transfemoral venous access were excluded.
The demographics of the study population are shown in Table 1 . One and 3 patients in the transhepatic and transsplenic groups, respectively, had received 2 or more repeat LTs prior to endovascular management of PV. The initial diagnoses of PV stenosis were based on enhanced computed tomography (CT; n 5 18) and/or Doppler ultrasound (US; n 5 15). Stenosis was diagnosed if CT revealed a nonenhanced PV segment or narrowing of the PV diameter by more than 50% of the adjacent normal extrahepatic PV and/or if US showed no flow in the main PV or an accelerated flow rate in the stenotic PV to more than 3-fold greater than that in the prestenotic PV.
TECHNIQUES
All procedures were performed under local anesthesia, which comprised subcutaneous and intramuscular injection of lidocaine (Jeil Pharm, Taegu, Korea) at the site of percutaneous transhepatic or transsplenic access and intravenous sedation (Demerol; Keukdong Pharm, Seoul, South Korea).
The access route for endovascular management of PV was selected using contrast-enhanced CT by an interventional radiologist (K.B.S. or G.Y.K.). Transsplenic access was considered the primary access route if the spleen was located in the normal position with splenomegaly, the splenic vein (SpV) was preserved without thrombosis, and the target lesion did not involve confluence of the superior mesenteric vein (SMV) and SpV. Accessibility of the percutaneous transsplenic puncture was confirmed via US in the angiography suite. Transhepatic access was chosen as the primary access route in all other situations.
Transsplenic Access
Percutaneous transsplenic puncture of the perihilar splenic venous branch was performed using a 21-gauge Chiba needle (Cook, Bloomington, IN) under US and fluoroscopic guidance, with the patient lying in a supine or oblique supine position. After successful puncture, the needle was exchanged for a 6-Fr coaxial dilator (Neff sheath; Cook) and a 6-7-Fr sheath (Radiofocus Introducer II sheath; Terumo, Tokyo, Japan or Flexor Ansel guiding sheath; Cook) over either a 0.016-or 0.018-inch micro guide wire (Cook or Terumo) or 0.035-inch angled hydrophilic guide wire (Glidewire; Terumo). A 5-Fr cobra or Kumpe catheter (AngioDynamics, Queensbury, NY) was then inserted into the PV system, and a direct SMV or SpV venogram and/or measurement of the pressure gradient across the PV stenosis were obtained. The 5-Fr catheter and a 0.035-inch guide wire were used to negotiate an intrahepatic PV across the PV stenosis or extrahepatic varices. Balloon angioplasty was initially performed to treat PV stenosis if the patient had undergone LT at least 4 weeks earlier. Stent placement was performed if a postangioplasty venogram showed an elastic recoil exceeding 50% of the prestenotic extrahepatic PV. Primary stent placement was performed if the patient had PV stenosis within 4 weeks after LT to minimize the risk of anastomotic disruption during balloon angioplasty. Poststenting balloon angioplasty was performed if a placed stent exhibited a circumferential deformity exceeding 30% of its normal diameter. Balloons with the same diameter or a 1-2-mm smaller diameter than that of the prestenotic extrahepatic PV were used, and self-expandable stents (Zilver stent; Cook or Prot eg e EverFlex stent; Covidien, Plymouth, MN) with the same diameter or a 1-2-mm larger diameter than the prestenotic extrahepatic PV were used. Stents with 8-14 mm in diameter and 4-8 cm in length were used to cover a stenosis with minimal angulation between the PV and the proximal and distal edges of the deployed stent.
Variceal embolization was performed using coils (Nester coils; Cook) or an Amplatzer vascular plug (AGA Medical Corporation, Golden Valley, MN) through a 5-Fr catheter or guiding sheath (Flexor Ansel guiding sheath; Cook), followed by a mixture (1:2 to 1:4) of glue (Histoacryl; B. Braun AG, Melsungen, Germany) and ethiodized oil (Lipiodol; Andre Guerbet, Aulnay-Sous-Bois, France) through a 2.2-Fr microcatheter (Terumo) to ensure complete embolization.
After the procedure, a venogram and/or measurement of the pressure gradient across the PV stenosis were obtained. The percutaneous transsplenic tract was embolized using 1 or 2 coils (Tornado embolization coil; Cook), followed by a mixture (1:2) of glue and ethiodized oil. The coils were detached immediately outside of the puncture point into SpV through a sheath dilator. Thereafter, the mixture was injected through a sheath dilator while the sheath and dilator were slowly withdrawn to occlude transsplenic parenchymal tract.
Transhepatic Access
Percutaneous transhepatic puncture of an intrahepatic PV branch was also performed using a 21-gauge Chiba needle as the transsplenic access. The remaining steps were the same as those described for the transsplenic access. The percutaneous transhepatic tract was also embolized using 1 or 2 coils, followed by a mixture (1:2) of glue and ethiodized oil through a sheath dilator.
FOLLOW-UP
The patient's vital signs were monitored in an intensive care unit or general ward every 4-8 hours. Liver function tests (LFTs) and complete blood counts were assessed before and approximately 1, 2, 3, and 7 days after the procedure. US was performed 1 day after the procedure to investigate the PV inflow, as well as postprocedural complications. CT within 1 week after the procedure was only performed in selected patients according to the physician's need to investigate PV and extrahepatic variceal flow and postprocedural complications. Postdischarge CT and/or US were performed arbitrarily at the physician's discretion.
The following parameters were documented retrospectively: technical success, pressure gradients across the stenosis before and after the procedure, complications, clinical success, and patency of PV. Technical success was defined as successful balloon angioplasty or stent placement in the intended location of PV, with subsequently improved PV inflow and <30% residual stenosis on postprocedural venography. For variceal embolization, technical success was defined as disappeared varices on postembolization venography. Major complications were defined as those necessitating an increased level of care, an additional surgical or interventional manipulation, adverse sequelae, or death according to the guidelines of the Society of Interventional Radiology Standards of Practice Committee. (8) All other complications were defined as minor complications. Clinical success was defined as a subsequent improvement in liver function with amelioration of clinical manifestations and postprocedural survival beyond 3 months. Patency of the PV inflow was evaluated using contrast-enhanced CT and/or US. across the PV stenosis. The analysis was performed using SPSS statistical software, version 21.0 (SPSS, Chicago, IL); a P value of < 0.05 was considered to indicate statistical significance.
STATISTICAL ANALYSIS
Results
The median interval between the last LT and the procedure was 233 days (range, 2-3387 days). Two and 3 patients in the transhepatic and transsplenic groups, respectively, underwent the procedure within 1 month after LT. Transhepatic access was selected because of a splenectomized state (n 5 3), target lesion involving the main PV, as well as confluence of SMV and SpV (n 5 3), or chronic SpV thrombosis (n 5 2). Transhepatic or transsplenic access was successfully achieved in all patients. These results are shown in Tables 2 and 3. A total of 12 of the 18 patients underwent stent placement: 3 had balloon angioplasty only; 2 had variceal embolization only; and 1 had variceal embolization followed by stent placement (Fig. 1 ). Stents were usually placed from the main PV to the proximal right PV (n 5 6) or in the main PV (n 5 3) across the PV anastomotic stenosis. However, 3 patients with stenosis in the main PV and confluence of the SMV and SpV underwent stent placement from the proximal SMV to the main PV via the transhepatic access. In 1 patient with a bilateral PV anastomotic stenosis following dual living donor left lobe LT, single stents were placed across each PV anastomosis via the transsplenic access (Fig. 2) . In this patient, the first stent was placed from the main PV to a right-sided left PV, and a second stent was placed into a left-sided left PV through the stent mesh of the first stent. One patient who had experienced in-stent restenosis 5 years after the third PV stent placement intentionally underwent balloon angioplasty only (7-mm-diameter drug-eluting and 12-mm-diameter conventional balloons) via the transsplenic access. In this patient, although postballooning venography indicated a remaining approximately 40% residual in-stent restenosis, repeat stent placement was not performed because of the patient's previous history of repeat stent placement, as well as improved PV inflow and the disappearance of duodenal varices (Fig.  3) . Embolization of large diameter (>10 mm) coronary varices and/or the splenorenal shunt was successfully achieved in all 3 patients.
Postprocedural venography revealed improved PV inflow with <30% residual stenosis in all except 1 patient who intentionally underwent transsplenic balloon angioplasty only. Therefore, we considered the technical success rates to be 100% in both the percutaneous transhepatic and transsplenic groups. The pressure gradient across the stenosis was measured in 14 of 16 patients who underwent balloon angioplasty or stent placement. The mean preprocedural and postprocedural pressure gradients were 10 6 7 (range, 2-24) mm Hg and 2 6 2 (range, 0-5) mm Hg, respectively (P < 0.001).
Regarding major complications, a SpV tear occurred in the patient who intentionally underwent balloon angioplasty only via the transsplenic access. In this patient, too much resistance was encountered when introducing a balloon catheter across the in-stent restenosis as a result of a tortuous SpV course, as well as the tight in-stent restenosis. Balloon angioplasty was finally achieved with the assistance of a Flexor Ansel guiding sheath. However, a SpV tear at the most tortuous portion of SpV was detected during sheath withdrawal. The patient's blood pressure decreased suddenly but was restored following a bolus infusion of normal saline. Extravasation disappeared following balloon inflation with a low pressure, across the tear point for 10 minutes. Thereafter, the patient received 3 units of whole blood. One-and 3-day follow-up nonenhanced CT scans showed a hematoma (maximal diameter, 7 cm) in the splenic hilar area without a change in size, and the patient was discharged 4 days after balloon angioplasty without remaining sequelae. Regarding minor complications, most patients complained of flank pain immediately after embolization of the transhepatic or transsplenic access route, which diminished after the administration of additional analgesics.
One-day follow-up US revealed improvements in the PV flow and ratio of the PV flow between the stenotic and prestenotic PV in all patients. However, 2 patients who underwent transsplenic balloon angioplasty only presented with a remaining stenosis of more than 30% of the placed PV stent or the extrahepatic PV. These patients did not undergo further treatment because the first experienced improved PV inflow and the disappearance of clinical manifestations, and the second underwent prophylactic balloon angioplasty. CT images obtained within 1 week after variceal embolization also confirmed well-occluded varices.
The median clinical follow-up period was 15 months (range, 2-28 months). Clinical success was achieved in 9 of 11 (82%) patients who had clinical manifestations. One patient each in the transhepatic and transsplenic groups died of hepatic failure-related sepsis or a reactivated viral hepatitis C infection without clinical improvement. The remaining 7 patients who received prophylactic endovascular treatment remained healthy when the current manuscript was written. Recurrent symptoms occurred in 1 patient following transhepatic stent replacement. This patient exhibited restenosis with partial thrombosis at the distal stent edge on 3-month follow-up CT, and PV inflow was restored via balloon angioplasty, followed by repeat stent placement. However, melena recurred 6 months later, and CT and direct PV venography revealed extensive thrombosis in the stent-placed PV. Thrombolysis and balloon angioplasty were performed via the transhepatic access; however, PV flow was not restored. The patient is now undergoing conservative management. One patient who exhibited in-stent restenosis after transsplenic balloon angioplasty only did not experience a recurrence of melena during a 24-month follow-up, although a further imaging study of PV patency was not performed.
The median imaging follow-up duration was 9 months (range, 1-28 months). Patency of the PV flow was maintained in 16 of 17 patients (except for the patient with failed thrombolysis). However, 2 of the 16 patients experienced restenosis. One patient who underwent transhepatic balloon angioplasty only had restenosis (50%) with an increased peak flow velocity ratio (6. 3) between the stenotic and prestenotic PVs on an 18-month follow-up US. The other patient who underwent transsplenic balloon angioplasty only also exhibited restenosis (40%) at the PV anastomosis on an 18-month follow-up CT. However, these patients did not undergo further treatment because of the lack of clinical manifestations.
Discussion
We found that percutaneous transsplenic access was feasible and relatively safe in LT recipients with splenomegaly. Although we experienced 1 major bleeding complication, balloon angioplasty, stent placement in PV, or variceal embolization was successfully achieved via this access, without injury to the engrafted liver. Endovascular management of PV is usually performed through a percutaneous transhepatic access. However, this type of access has several limitations. First, it may present a risk to the liver graft in the form of intrahepatic pseudoaneurysm or subcapsular hematoma. Although our patients who underwent management via the transhepatic access did not experience any bleeding complications, bleeding is a well-known complication associated with percutaneous transhepatic interventions.
(9-12) Ko et al. (12) reported 2 cases of hemoperitoneum caused by blood oozing from a transhepatic tract and 1 case of intrahepatic pseudoaneurysm following percutaneous transhepatic PV stent placement in 9 patients within 1 month after LT. Second, PV puncture is not easily achieved if the intrahepatic PV branches are collapsed because of extrahepatic PV stenosis or occlusion. (1) In the current study, we selected a transsplenic access for 1 patient in whom a severely collapsed intrahepatic PV was evident on preoperative CT, and successfully achieved stent placement. Third, a single transhepatic access might not be appropriate for the management of all target lesions in a specific situation. We selected a transsplenic access in 1 patient who presented with bilateral PV anastomotic stenosis after dual living donor LT and were able to place sequential dual stents successfully in the rightand left-sided PVs. Therefore, we believe that percutaneous transsplenic access is a useful alternative, especially in patients with collapsed intrahepatic PVs or those in an early post-LT state.
Several investigators reported that PV intervention via the transsplenic access was feasible and safe in LT recipients.
(1,3,13) Cheng et al. (1) performed PV recanalization via the transsplenic access in 8 of 20 procedures in 16 LT recipients, and reported a 75% (6/8) success rate without major complications when using this access compared with a 70% (7/10) success rate and 1 major bleeding complication when using a transhepatic access. The authors concluded that the transsplenic access is less injurious to the transplanted liver and could be an alternative route for PV interventions in LT recipients for whom a conventional transhepatic access would be challenging.
Percutaneous transsplenic puncture of a perihilar splenic venous branch may be very difficult or dangerous in patients with normal-sized spleens because the spleen is located posteriorly in the left upper quadrant of the abdomen. However, splenomegaly consequent to preoperative chronic liver disease or cirrhosis is relatively common in LT recipients, and engorgement of the intrasplenic venous branches is frequently accompanied by PV stenosis or splenomegaly. Therefore, transsplenic access into SpV is usually not difficult to achieve in LT recipients with splenomegaly who are placed in the supine position. All patients in our transsplenic access group had splenomegaly, and access into SpV was achieved successfully from the left midaxillary or posterior axillary line, although some patients with mild splenomegaly required placement in an oblique supine position. Zhu et al. (6) reported a 96% success rate when using the transsplenic access to treat gastroesophageal variceal bleeding or place PV stents in 46 consecutive patients with portal hypertension and splenomegaly.
The SpV course and target lesion location also seem to be important factors when determining a PV intervention via the transsplenic access. The SpV course may be extremely tortuous because of splenomegaly, which might hinder the introduction of a catheter, balloon catheter, or stent introducer into the target lesion. We experienced a SpV tear in 1 patient with a tortuous SpV course, as well as PV in-stent restenosis, and we attributed this complication to the tortuous SpV course. In the current study, we chose the transhepatic access if the target lesion was located in the main PV, as well as in cases involving confluence of the SMV and SpV; in such situations, balloon angioplasty may be easily achieved via the transsplenic access. However, we thought that stent placement via the transsplenic access might not guarantee longterm patency because of an insufficient stent landing zone at the confluence of the SMV and SpV or misalignment of stents placed from the SMV to the main PV. Therefore, a precise interpretation of the SpV course and locations of target lesions using preprocedural CT will allow a successful and safe PV intervention via the transsplenic access.
Although the transsplenic access is an attractive alternative route to PV, this access remains controversial because of concerns regarding bleeding from the spleen. Several investigators have reported various transfusion rates following embolization of the transsplenic route using gelfoam (12%), (14) glue (11%), (6) or a combination of gelfoam and coils (28%). (4) However, other investigators reported no major bleeding complications and no required transfusions after embolization of the transsplenic route using a combination of coils and glue.
(1-3,7) Interestingly, Cheng et al. (1) reported successful embolization of the transhepatic or transsplenic tract using coils and glue in 12 patients, and observed a major bleeding complication in 1 patient following embolization using only gelatin sponge cubes. In the current study, no patient experienced bleeding complications following embolization of the transhepatic or transsplenic tract when a combination of coils and glue was used. Therefore, we believe that embolization using a combination of coils and glue may effectively prevent tract bleeding.
Currently, the treatment of choice for post-LT PV stenosis or occlusion is percutaneous balloon angioplasty or stent placement. "Leave nothing behind" is the main advantage of balloon angioplasty. However, this technique is limited by a high incidence of restenosis. (10, 15, 16) Stent placement usually has a high initial success rate and acceptable longterm patency. However, it also has several potential complications, including in-stent restenosis, thrombosis, or difficulty with reanastomosis during retransplantation. (12, 17) In the current study, all 3 patients who underwent balloon angioplasty only exhibited restenosis during follow-up imaging studies, despite the absence of specific clinical manifestations. In comparison, 12 of 13 patients who underwent stent placement had patent PVs until the last follow-up imaging study. Although 1 patient finally resulted in PV thrombosis after 2 additional stent revision sessions, we assume that this outcome might have been attributable to the interposition jump graft between the SMV and PV. Therefore, we believe that stent placement may be more effective than balloon angioplasty for the management of symptomatic PV stenosis, although our follow-up period was limited.
In conclusion, although we had a relatively small number of study patients, we have demonstrated the feasibility and relative safety of percutaneous transsplenic PV intervention. Therefore, we consider this access to be an effective, nonliver graft-damaging alternative for PV intervention in LT recipients with splenomegaly.
